TACE With Thermosensitive Nanogel Versus Embosphere for HCC
Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18-80
SponsorZhongda Hospital
About this trial
To verify the safety and efficacy of TACE withThermosensitive Nanogel Embolic Agent for HCC.
Eligibility criteria
Qualifiers
Chinese Liver Cancer Staging Scheme, stage IIb-Illa, as well as those with stage Ia-Ila HCC, unsuitable or unwilling to undergo surgical resection, transplantation, or ablation;
Liver function status: Child-Pugh A or B
Eastern Cooperative Oncology Group score: 0-2 points;
With at least one measurable, unembolized liver tumor lesion (1-10 cm) ;
Disqualifiers
The target lesion has been embolized before or require combined with other treatment(s);
Diffuse or with extrahepatic metastasis;
Coagulation dysfunction (PT prolonged beyond the upper limit of normal for 3 seconds);
Severe renal dysfunctions (creatinine clearance rate <30 ml/min);
Trial design
Treatments tested in this trial
- Thermosensitive Nanogel Embolic Agent
Treatment groups
188 Participants
are divided into 2 treatment groupsSponsors and collaborators
Source ClinicalTrials.gov